Pasireotide

What it's for

Pasireotide is a somatostatin analog with broader receptors (lock-and-key landing spots on cells) subtype affinity (including SSTR5) than octreotide/lanreotide. Treats Cushing’s disease and acromegaly in appropriate adults when surgery is not an option or has not cured disease, per labels.

What it does for the body

Treats Cushing’s disease and acromegaly in appropriate adults when surgery is not an option or has not cured disease, per labels. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

Broader SSTR activating its target pathway suppresses ACTH (the pituitary signal that tells the adrenals to make cortisol) or growth hormone secretion (acromegaly). Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Pasireotide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Hormones research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Pasireotide — FDA.gov search
• ClinicalTrials.gov search: Pasireotide — U.S. clinical trials registry
• Drugs@FDA search: Pasireotide — FDA drug database (if approved)
• PubMed search: Pasireotide — NCBI PubMed
• PubMed Central search: Pasireotide — NCBI PMC

Reference

No ref on file.